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Background: The purpose of this study is to evaluate the prognostic value of TFPI-2 expression in breast cancer
patients through examining the correlation between TFPI-2 expression and breast cancer clinicopathologic features.
Methods: Immunohistochemical staining combined with digital image analysis was used to quantify the expression
of TFPI-2 protein in breast tumor tissues. For evaluation of the prognostic value of TFPI-2 expression to each
clinicopathologic factor, Kaplan-Meier method and COX’s Proportional Hazard Model were employed.
Results: TFPI-2 expression was significantly correlated with tumor size, lymph node metastasis, histologic grade,
clinical stage, and vessel invasion. More importantly, TFPI-2 expression was also associated with disease-free survival
(DFS) of breast cancer patients. We found that patients with high TFPI-2 expression had longer DFS compared with
those with low or negative expression of TFPI-2 (P <0.05, log-rank test). Cox’s regression analysis indicated that TFPI-2
expression, histologic grade, and vessel invasion might be significant prognostic factors for DFS, while TFPI-2
expression and histologic grade were the most significant independent predictors for tumor recurrence. Compared
with the group with low/high TFPI-2 expression, the TFPI-2 negative group was more likely to have tumor relapse. The
hazard ratio of DFS is 0.316 (P <0.01).
Conclusions: Low or negative expression of TFPI-2 is associated with breast cancer progression, recurrence and poor
survival outcome after breast cancer surgery. TFPI-2 expression in breast tumors is a potential prognostic tool for breast
cancer patients.
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Breast cancer remains the most frequent malignant tumor
in women worldwide and is one of the leading causes of
cancer-related mortality [1], while metastasis is the main
reason for treatment failure of breast cancer. Better under-
standing of underlying mechanisms of breast cancer me-
tastasis should contribute to the treatment and prevention.
A common consensus is that breast cancer metastasis is a
multi-gene involvement and multi-step process that lead to
the reduction of intercellular adhesion and degradation of
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reproduction in any medium, provided the ortumor metastasis [2,3]. Breast cancer cells secrete a
variety of matrix metalloproteinases (MMPs) and active
plasminogen, which hydrolyses ECM and facilitates tumor
invasion and metastasis [4-6].
Human tissue factor pathway inhibitor-2 (TFPI-2) is a
kunitz-type serine proteinase inhibitor, which is pro-
duced and secreted into ECM by endothelial cells,
smooth muscle cells, fibroblasts, keratinocytes, and
urothelium [7,8]. It is documented that TFPI-2 strongly
prevents ECM hydrolysis by inhibiting plasmin and
MMPs [9,10]. Recent studies show that the expression of
TFPI-2 is down-regulated in several invasive tumor cell
lines, including choriocarcinoma, glioma, prostate cancer,
melanoma, fibrosarcoma, and pancreatic ductal adenocar-
cinoma, while exogenous expression of this gene in cancer
cells can inhibit tumor growth and metastasis in vivo by
modulating ECM remodeling and angiogenesis [11-16].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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invasive breast cancer cell lines due to hypermethylation
of TFPI-2 promoter [17]. Similarly, several studies indicate
that aberrant methylation of TFPI-2 gene promoter is
found to be associated with a variety of malignant tumors
[18-20]. These studies together suggest that TFPI-2 may
be involved in tumor progression and have a potential
prognostic value in cancer patients. The purpose of
current study is to reveal the potential correlation between
TFPI-2 expression level and clinicopathologic features by
examining the expression level of TFPI-2 in tumor sam-
ples, in order to provide some meaningful insights to its
value as a prognostic factor in breast cancer.
Methods
Specimen cohorts
Specimens were obtained from the female patients who
were treated at department of breast surgery of
Zhongshan Hospital affiliated to Fudan University from
January 2005 to May 2008. From a total of 445 consecu-
tive patients with operable primary breast cancer, we
randomly selected 156 invasive breast cancer patients’
paraffin blocks of tumor tissues for our study (random num-
bers table) after excluding the patients with neoadjuvant
chemotherapy or positive margins on histopathology. All pa-
tients received breast cancer surgery and standardized adju-
vant therapy. Meanwhile, 40 benign breast tumor tissues
were collected as controls. The selected breast cancer pa-
tients were divided into three groups according to cTNM
staging system of American Joint Committee on Cancer
(AJCC), including 40 patients in stage I, 74 patients in stage
II, and 42 patients in stage III. In our specimens, 34 cases
that had vessel invasion were defined as the presence of neo-
plastic emboli in two or more blocks [21].
We followed up the selected patients through phone or/
and outpatient visits every month from one month after
surgery till August 2011, and the follow-up was ended up
with 118 patients with a median of 39 months (range of 2
to 75 months). 38 patients were lost in the follow-up. We
found that 33 patients suffered from local recurrence or
distant metastasis after surgery, in which local or regional
recurrence was confirmed by histology and distant metas-
tasis was detected by biopsy or imaging techniques. 7 pa-
tients died, with five of them due to breast cancer. 85
patients were found free of tumor recurrence. This study
was approved by the Research and Ethical Committee of
Zhongshan Hospital affiliated to Fudan University.
Immunohistochemical staining
Immunohistochemical staining was performed by a two-
step assay on 4-μm thick tumor sections. Briefly, tissue
slides were de-paraffinized with xylene and re-hydrated
through alcohol gradient washes. Antigen retrieval was
carried out by immersing the slides in citric acid fixsolution (pH 6.0) for 20 minutes at 95°C. The endogen-
ous peroxidase activity was blocked by incubation in a
0.3% hydrogen peroxide buffer for 15 minutes. The sec-
tions were rinsed in Tris-HCl-buffered saline (pH7.6)
and incubated with 3% bovine serum albumin to block
nonspecific staining, and then incubated with a mouse
polyclonal anti-TFPI-2 antibody (1:2000) overnight at
4°C in a humidified chamber. The mouse polyclonal
anti-TFPI-2 antibody was generated by immunizing mice
as previously reported [22]. The sections went through a
stringent washing session before being incubated with the
secondary antibody (horseradish peroxidase-conjugated
rabbit anti mouse immunoglobin, EnVision Detection Kit
A solution, Gene Tech, Hk) for 30 minutes at room
temperature. Diaminobenzidine (EnVision Detection Kit
B+C solution) was used as a chromogen, and sections were
counterstained with hematoxylin. The placenta tissue sec-
tions were used as positive controls, and the buffer for dilu-
tion of primary antibody as a negative control. The staining
intensity in cytoplasm was quantified as described below.
Semi-quantitative analysis of immunohistochemical
staining sections
All immunostained slides were analyzed by two patholo-
gists independently in a blinded manner. Results from two
pathologists were identical in most cases, and discrepancies
were resolved by re-examination and consensus. No stain-
ing signal or staining signals present in less than 10% of
tumor cells was considered as negative otherwise was con-
sidered positive. All the positive-staining sections were
quantified using a computerized image system which was
composed of OLYMPUS DP71 camera and OLYMPUS
BX51 microscope, with the photo resolution of 13 million
pixels. Six representative fields (200×objective) were picked
up from hot-spot areas on every slide with identical set-
tings (including do shading correction and white balance)
for quantification of immunohistochemical densities.
We used Image-Pro Plus 6.0 software (Media Cybernetics,
Inc., Silver Spring, MD) for image analysis, which gener-
ated the integrated optical density (IOD) of TFPI-2 stain-
ing as well as the area of target protein distribution in
each slide, as shown in Equation 1. In general, IOD value
is proportional to the amount of target protein. The mean-
density was obtained with IOD value divided by area (as
shown in Equation 2), which represents the amount of
target protein (TFPI-2) per unit area. Figure 1 shows repre-




density x; yð Þds ð1Þ
density meanð Þ ¼ IOD=area ð2Þ
Figure 1 Semi-quantification of immunostaining by digital image analysis. (A) The original photograph acquired from tissue sections. Black
arrow indicates the positive staining cells, and white arrow indicates the negative staining stroma area. (magnification×200). (B) Marking the
sections. The positive staining cytoplasm that is chosen as the color of interest and masked with red color. (C) The area of positive staining which
is marked by red lines (excluded the noisy spots less than 50 pixels). The exact number of positive staining area which labeled by green spots.
(D) The area of positive staining which is marked by red lines (excluded the noisy spots less than 50 pixels). The exact number of positive
staining IOD which is labeled by green spots. IOD divided number of positive staining area is mean-density that represented the concentration of
TFPI-2 expression.
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mean-density value which is obtained by averaging the
density of six visions on each slide.
Statistical analysis
The differences in clinicopathologic features between
the TFPI-2 negative group and the positive group were
determined using Pearson’s χ2 test. In the TFPI-2 posi-
tive group, the correlation between TFPI-2 expression
and clinicopathologic characteristics was tested using T
test or ANOVA. Disease-free survival (DFS) was defined
as the time period from the date of surgery operation to
the first recurrence (local or distant) or death from
breast cancer without a recorded relapse. The survival
curves of each group were estimated by Kaplan-Meier
survival analyses, and the curves were compared using
log-rank tests. In multivariate analysis, a COX’s Propor-
tional Hazard Model was applied to determine whether
a factor was an independent predictor of survival. All
statistical tests were two-sided, and P values less than
0.05 were considered as statistically significant. The stat-
istical analyses were performed using SPSS 18.0 software
(SPSS Inc.).Results
Immunohistochemical tissue staining
We found that TFPI-2 staining was observed mainly on
the cytoplasm of cells in breast glandular tissue or breast
tumor tissue. Although sporadic positive staining was
found on stroma areas, most of these areas showed
negative staining. Strong positive staining could be ob-
served in almost all benign breast tumors, while in
breast cancer tissues, either positive staining or negative
staining could be found. In general, the TFPI-2 staining
tended to be weaker in breast cancer tissues than that in
benign breast tissue, as shown in Figure 2 (A-D).
Correlation of TFPI-2 Expression and clinicopathologic
features
Altogether, we obtained 196 female patients in this
study, including 156 breast cancer patients and 40 be-
nign breast tumor patients. The median age of breast
cancer patients was 54 years old (range of 29 to 95 years
old). The median age of benign breast tumor patients was
38 years old (range of 21 to 55 years old). Almost all be-
nign breast tumors exhibited high levels of TFPI-2 expres-
sion, with a mean of mean-density of TFPI-2 staining as
Figure 2 Immunohistochemical staining for TFPI-2 expression in breast tumors. (A) A representative TFPI-2 positive staining image using
sections of hyperplasia of mammary glands. (B) A representative TFPI-2 positive staining image using sections of intraductal papillomas. (C) A
representative TFPI-2 positive staining image using sections of breast cancer. (D) A representative TFPI-2 negative staining image using sections
of breast cancer. (magnification×200).
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tients, 22.4% (35 of 156) of patients were TFPI-2-negative
(including 19 cases with no staining signal and 16 cases
with staining cells <10%), while the remaining 77.6% (121
of 156) showed variable levels of TFPI-2 expression, with
a mean of mean-density of this cohort as 0.325 (95% CI
0.315-0.336).
We further stratified these 156 breast cancer patients
as TFPI-2 positive and TFPI-2 negative groups according
to the TFPI-2 staining of tumor sections. We found that,
compared with patients with TFPI-2 positive breast can-
cer, patients with TFPI-2 negative had higher proportion
of lymph node metastasis and poor differentiation in
histology and more common vessel invasion. However,
the differences of patient’s age, pathological type, clinical
stage, and expression of hormone receptor and HER-2
in two groups did not appear to have any correlation
with TFPI-2 expression (Table 1).
In the TFPI-2 positive breast cancer group, we com-
pared the mean-density, which represent the level ofTFPI-2 protein, with the clinicopathologic features in-
cluding many common predictors of survival (Table 2).
We found that multiple clinicopathologic features, such
as tumor size, skin involvement, lymph node metastasis,
histologic grade, clinical stage, and vessel invasion, were
significantly correlated with the mean-density of TFPI-2
staining (Table 2, P<0.05). The result suggests that breast
cancer patients with lower level of TFPI-2 tend to
present more advanced cancer features such as larger
tumor, skin involvement, positive lymph nodes, poorer
histologic grade, later clinical stage, presence of vessel
invasion and so forth. Nevertheless, patient’s age, patho-
logical type, and expression of hormone receptor and
HER-2 have little association with TFPI-2 protein levels.
The results above are corresponding to the results in
Table 1.
TFPI-2 expression and survival
In a total of 118 patients with followed-up, we found
that 91 cases with TFPI-2 positive breast cancer. We








≤55 24(68.6%) 74(61.2%) 0.639 0.424
>55 11(31.4%) 47(38.8%)
Tumor size
≤2 cm 12(34.3%) 56(46.3%) 1.589 0.208
>2 cm 23(65.7%) 65(53.7%)
Skin involvementa
No 30(85.7%) 96(79.3%) 0.710 0.399
Yes 5(14.3%) 25(20.7%)
LN metastasis




≤II 13(37.1%) 71(58.7%) 5.066 0.024
>II 22(62.9%) 50(41.3%)
Vessel invasion




















IDCb 29(82.9%) 98(81.0%) 0.062 0.803
Non-IDCc 6(17.1%) 23(19.0%)
a skin involvement include: edema, redness, nodularity, or ulceration of
the skin.
b IDC, invasive ductal carcinoma.
c Non-IDC include: invasive lobular carcinoma, mucinous or colloid carcinoma,
medullary carcinoma, metaplastic carcinoma.
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median of TFPI-2 mean-density at 0.324. As shown in
the Figure 3, patients with higher TFPI-2 expression
(above the mean value) tended to have longer DFS com-
pared with those with lower or negative expression.
More importantly, we found that the group with nega-
tive TFPI-2 expression was statistically significantly asso-
ciated with poorest DFS among these 118 patients (P <
0.05, log-rank test).
Furthermore, a multivariate COX ’s Proportional Hazard
Model, in which tumor size, LN metastasis, histologic
grade , vessel invasion, and TFPI-2 expression were in-
cluded, showed that loss of TFPI-2 expression was an
independent prognostic factor for DFS in breast cancer
patients (Exp(B)=0.316, 95.0% CI 0.191~0.532, P <0.01).
The results also showed that low histologic grade and ves-
sel invasion were independent unfavorable factors for
DFS, while poorer histologic grade appeared to have
more significant impact on DFS (histologic grade ≤II
vs. >II, Exp(B)=3.073, 95.0% CI 1.404~6.729, P=0.005)
(Table 3).
Discussion
Human tissue factor pathway inhibitor-2 (TFPI-2) is a
kunitz-type serine proteinase inhibitor that plays a crit-
ical role in extracellular matrix (ECM) remodeling and
homeostasis [9]. The ECM provides a scaffold for epithe-
lial cells and contributes to cell apoptosis, proliferation,
adhesion, migration, and differentiation, which are critical
to tumor progression [2,23]. TFPI-2 inhibits the activity of
plasmin and a variety of matrix metalloproteinases
(MMPs), which are important to tumor invasion and me-
tastasis. Our previous studies, along with the reports by
others [17-19], indicate that dysregulation of TFPI-2 is as-
sociated with tumor progression.
Breast cancer originates in mammary epithelial cells,
with a clear tendency to lymph node and blood metasta-
sis. Before metastasis, cancer cells must degrade and
destroy extracellular matrix and permeate the basement
membrane [24]. It has been shown that breast cancer
cells can secrete a variety of matrix metalloproteinases,
and breast cancer cells with higher degree of malignancy
appear to produce more types and amounts of MMPs
[25]. Urokinase-type plasminogen activator (uPA) recep-
tor, which lies on the surface of breast cancer cells, com-
bines with free uPA in ECM and converts more
plasminogen into plasmin [26-28]. Plasmin is also an ac-
tivator of MMPs. Moreover, trypsin, chymotrypsin,
plasma kallikrein can also activate pro-MMPs. TFPI-2
can inhibit activity of these enzyme, but also can directly
inhibit the activity of MMPs [10,29]. The hydrolysis of
ECM by plasmin and MMPs is the key steps for the
tumor invasion and metastasis. In normal cells, TFPI-2
can inhibit plasmin and MMPs, reduce degradation of








Age ≤55 74 0.324±0.061 t=0.302 0.764
>55 47 0.327±0.052
Tumor size ≤2 cm 56 0.351±0.061 t=4.948 0.001
>2 cm 65 0.303±0.044
Skin involvementa No 96 0.336±0.057 t=4.252 0.001
Yes 25 0.284±0.038





Histologic grade ≤II 71 0.339±0.057 t=3.389 0.001
>II 50 0.305±0.052
Vessel invasion Absence 109 0.333±0.054 t=5.172 0.001
Presence 12 0.251±0.030
Clinical stagec I 35 0.375±0.053 Chi-Square=43.867c 0.001
II 52 0.317±0.048
III 34 0.286±0.034
ER (-) 43 0.327±0.055 t=0.253 0.801
(+) 77 0.324±0.059
Unknown 1
PR (-) 63 0.319±0.055 t=-1.211 0.228
(+) 57 0.332±0.060
Unknown 1
HER-2 (-) 62 0.333±0.059 t=1.361 0.176
(+) 55 0.318±0.056
Unknown 4
Tumor type IDCd 98 0.324±0.057 t=0.488 0.626
Non-IDCe 23 0.330±0.059
a skin involvement include: edema, redness, nodularity, or ulceration of the skin.
b Post Hoc Multiple Comparisons(LSD) shows difference of TFPI-2 expression is only present in the group without LN metastasis and the other groups.
c Post Hoc Multiple Comparisons(Games-Howell) shows difference of TFPI-2 expression was significant among the groups (Nonparametric Test).
d IDC, invasive ductal carcinoma.
e Non-IDC include: invasive lobular carcinoma, mucinous or colloid carcinoma, medullary carcinoma, metaplastic carcinoma.
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thelial growth factor that is involved in promoting tumor
angiogenesis by a negative feedback mechanism [30-32].
The reduction of TFPI-2 expression may weaken the in-
hibition of MMPs and plasmin, promote the develop-
ment of malignant behavior in breast cancer. Early
studies of our research group found that TFPI-2 showed
low or negative expression in highly invasive breast can-
cer cell lines because the CpG islands in TFPI-2 pro-
moter was hypermethylated, and DNA methylation in
the promoter region induced inactive chromatin struc-
ture and decreased KLF6 binding to its DNA bindingsequence [17]. Exogenous expression of TFPI-2 may in-
hibit the malignant behavior of breast cancer cell line
MDA-MB-435 in nude mice [17]. These results suggest
that TFPI-2 is inversely related to the ability of invasion
and metastasis of breast cancer.
In our present study, we further investigated the cor-
relation between TFPI-2 expression and clinicopatho-
logic features of breast cancer. We found that breast
cancer tissues tended to have weaker degree or less por-
tion of TFPI-2-positive staining than benign breast
tumor tissues. Compared with TFPI-2-positive breast
cancer patients, the TFPI-2-negative group had higher
Figure 3 Kaplan–Meier analyses of the effect TFPI-2 expression on disease-free survival.
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tiation in histology and more common vessel invasion.
The histopathological parameters were found to be sig-
nificantly associated with TFPI-2 (P<0.05). These find-
ings indicate that loss of TFPI-2 expression in breast
cancer is likely to contribute to the permeation of cancer
cells into the basement membrane and metastasis. In the
TFPI-2-positive breast cancer patients, we found that
lowered expression of TFPI-2 seemed to be associated
with advanced progress of breast cancer like larger
tumor size, skin involvement, positive lymph nodes, later
clinical stage, presence of vessel invasion, poorerTable 3 Multivariate Analyses of DFS (Backward Stepwise
(Likelihood Ratio))
Variable HR 95%CI P value
Tumor size
(≤2 cm vs >2 cm) 0.715 0.335 to 1.529 0.387
LN metastasis
(No vs Yes) 1.028 0.459 to 2.298 0.947
Histologic grade
(≤II vs >II ) 3.073 1.404 to 6.729 0.005
Vascular invasion
(No vs Yes) 0.534 0.219 to 1.298 0.166
TFPI-2
(negative vs low/high expression) 0.316 0.191 to 0.523 0.001histologic grade etc. Further survival analysis indicates
that patients with high TFPI-2 expression have longer
DFS compared to the others with low or negative ex-
pression. Negative expression of TFPI-2 is significantly
associated with poorest DFS in these 118 patients (P < 0.05,
log-rank test).
The peak time for breast cancer recurrence and metas-
tasis is 1~3 years after surgery [1]. Local recurrence and
distant metastasis indicate the failure of treatment in
breast cancer. It is believed that local recurrence rarely
occurs independently, which is often a harbinger of dis-
tant metastasis. Although adjuvant therapies improved
long-term survival in breast cancer patients, thousands
of people died of metastasis. Thus, further study on
breast cancer recurrence and metastasis is essential to
breast cancer treatment. Traditionally, tumor size, LN
metastasis, and histologic grade are still the most im-
portant prognostic indicators. However, we found some
patients with a relatively early TNM stage suffered from
local or distant metastasis in our follow-up process. Cox
regression analysis was applied to determine significant
prognostic factor. The result shows that TFPI-2 expres-
sion and histologic grade are the significant prognostic
factors. Patients with lower TFPI-2 expression are more
likely to relapse. Moreover, we found that the hazard ra-
tio (Exp(B)) of DFS is 0.316 (P <0.01), indicating that the
group with lower TFPI-2 expression may have about 3
times more risk of breast cancer relapse. The results
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should receive more effective systemic therapy to reduce
tumor recurrence.
Tumor occurrence and development can be consid-
ered as the accumulation of gene mutations and epigen-
etic modifications. The predominant consequence of this
accumulation is the activation of proto-oncogenes or si-
lencing of tumor-suppressor genes [33]. Consistent with
previous reports that TFPI-2 can inhibit the occurrence
or development of malignant tumors through various
mechanisms, our results show the expression of TFPI-2
in breast benign tissue is significant higher than that in
breast malignant tumor, and the advanced extent of
breast cancer is correlated with lower expression of
TFPI-2. More importantly, we found that the patients
with TFPI-2-negative are significantly associated with
poorest DFS, and patients with higher TFPI-2 expression
have better cumulative survival. These results together
indicate that TFPI-2 may act as a tumor suppressor in
the development of breast cancer and could well be con-
sidered as a novel biomarker for prognosis and therapy
in breast cancer.
Conclusions
Low or negative expression of TFPI-2 is associated with
breast cancer progression, recurrence and poor survival
outcome after breast cancer surgery. TFPI-2 expression
in breast tumors is a potential prognostic tool for breast
cancer patients.
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